Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiovascular outcomes
Pharma
Novo's oral semaglutide shows heart benefits
Armed with the positive phase 3 readout, Novo said it plans to file Rybelsus for cardiovascular outcomes approvals “around the turn of the year.”
Angus Liu
Oct 21, 2024 10:09am
Novo bolsters star power of obesity blockbuster Wegovy
May 14, 2024 11:40am
ESC says SGLT2s like Farxiga are first-line treatment in HF
Aug 28, 2021 1:35pm
Bayer's Kerendia racks up cardio benefits in outcomes trials
Aug 28, 2021 11:25am
Amarin touts Vascepa in preventing repeat heart problems
Aug 23, 2021 11:58am
Fujifilm, WuXi STA, Hanmi, BeiGene and more—Fierce Pharma Asia
Jul 2, 2021 9:28am
